14th Dec 2006 09:10
Stem Cell Sciences plc14 December 2006 14 December 2006 Stem Cell Sciences Makes Strategic Appointment Stem Cell Sciences plc (SCS, AIM:STEM), the global biotechnology company focusedon the commercialisation of stem cells and stem cell technologies for researchand clinical applications, is pleased to announce the appointment of DavidCampbell as Group Business Development Manager. David, whilst based in Australia, will be responsible for the global businessdevelopment of Stem Cell Sciences' technologies facilitating the integration ofAustralian, Asian, European and US business development. David will travelextensively in this role and will be involved in all elements of SCS' growth andcommercialisation strategy across the four business units. He will report to theChief Operating Officer located in Edinburgh. David has over 25 years of experience in product and business development;commercialisation of technologies; marketing, logistics and general management.His experience spans the life sciences, agribusiness and chemical industries,the research sector and government interaction. Prior to joining SCS David held senior operational and business developmentpositions at Monash Commercial Pty Ltd, Monsanto Australia Limited, LinfoxGroup, and Pivot Ltd. As Director of Commercialisation at Monash Commercial heled business development in the biomedical field and was a Board member of earlystage spin-outs such as CNSBio Pty Ltd, Pulmosonix Pty Ltd and Cortical Pty Ltdas well as the CRC for Innovative Dairy Products. "The appointment of David Campbell brings a strategic and commercial focus tothe development of our business and international team and will greatly assistus in meeting our targets for growth and expansion in the global market," saidDr Peter Mountford, CEO of Stem Cell Sciences. "I am delighted to be joining Stem Cell Sciences. I look forward to working withthe international team in the development of the strategic plans for thebusiness. It is an exciting time for stem cell research and the commercialopportunities this offers on a global basis," said David Campbell. - Ends- -For further information, please contact:Stem Cell SciencesDavid Newton +61 (0)414 698 549 Talk BiotechFay Weston +61 (0)422 206036 Notes to EditorsStem Cell Sciences plc (SCS, AIM: STEM) is a global biotechnology company,established in Melbourne, Australia in 1994, providing products in theburgeoning stem cell research and drug discovery markets, in addition to thetargeted development of cell-based therapies for neurodegenerative disease andinjury. The Company has established a leading intellectual property (IP) and technologyportfolio that enables the commercial application of stem cells in drugdiscovery, providing the Company with early-stage revenue streams and technologydevelopment for at scale cell production of SCS cell-based therapeutics. SCSprincipal focus is in neurological disease. Revenues in the neurotech market,including pharmaceuticals, devices and diagnostics, grew 10% in 2005 to US$110billion (Neurotech Insights, Volume 2/3 April 30 2006). SCS operates as a group of independent operations with laboratories in Scotland,Japan and Australia, each of which is affiliated with an academic centre ofexcellence. These include the Institute of Stem Cell Research (ISCR), Edinburgh,UK, RIKEN Centre for Development Biology, Kobe, Japan and the Australian StemCell Centre, Melbourne, Australia. SCS has four business units focused on key sustainable business strategies. SC Proven(R) provides cell culture media (liquid formulations) and reagents thatenable the growth and differentiation of stem cells. The first commerciallyavailable product, a novel, serum free, stem cell growth medium, has beenexclusively licensed for manufacture and marketing to Chemicon, part ofMillipore Corporation. SC Licensing licenses SCS proprietary technologies, such as Internal RibosomeEntry Site (IRES) and Stem Cell Selection, for application in laboratory-basedresearch and discovery. SCS has licensed technology to major pharmaceutical andbiotechnology companies including Pfizer, Sanofi Aventis, GSK, Deltagen Inc andLexicon Genetics Inc. SC Services provides specialised stem cell production for basic research anddrug discovery, including high-throughput applications. SC Therapies' goal is to develop safe and effective cell-based therapies forcurrently incurable diseases. SCS is conducting preclinical evaluations of itsneural stem cell lines in a number of therapeutic applications. The firstpreclinical programme is being undertaken by SCS' Japanese affiliate, whichrecently announced the exclusive licensing of human multi-potent adipose-derivedstem (hMADS) cells for therapeutic purposes. SCS KK will conduct preclinicalstudies for the treatment of Duchenne Muscular Dystrophy in 2007-8. For further information on the company please visit:www.stemcellsciences.com This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SThree